DCAL167.18

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,621 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-2.730.061.461.46
Return on Assets-1.600.030.820.82
Return on Capital Employed-0.352.172.362.36
Return on Invested Capital-0.330.932.441.58
Margins
EBITDA Margin10.9517.2919.2916.72
Operating Margin-0.936.467.747.74
Incremental Operating Margin208.4623.48
Pretax Margin-4.670.713.580.52
Net Income Margin-5.870.123.320.56
Net Income to Common Margin-5.870.123.320.56
FCF Margin3.095.847.697.69
Additional
Effective Tax Rate-25.5183.227.10-7.66
Sustainable Growth Rate-2.730.061.461.46
Incremental Operating Margin %208.4623.48295.73
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.